The study indicates that increased DUSP1 levels can cause anti-HER2 therapy resistance, and disruption of HER2+ DUSP1 signaling has more benefit to treat breast cancer, suggesting that DUSP1 is involved in immunotherapy resistance directly or indirectly.141. This evidence concerns the gene ERBB2 and breast carcinoma.